Characterization of the 5-HT(2C) receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity

The 5-HT(2C) receptor agonist lorcaserin (Belviq®) has been Food and Drug Administration (FDA) approved for the treatment of obesity. The present study is a back translational investigation into the effect of 28-day lorcaserin treatment in a diet-induced obesity (DIO) model using male, Sprague–Dawle...

Descripción completa

Detalles Bibliográficos
Autores principales: Higgins, Guy A, Desnoyer, Jill, Van Niekerk, Annalise, Silenieks, Leo B, Lau, Winnie, Thevarkunnel, Sandy, Izhakova, Julia, DeLannoy, Ines AM, Fletcher, Paul J, DeLay, Josepha, Dobson, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317222/
https://www.ncbi.nlm.nih.gov/pubmed/25692009
http://dx.doi.org/10.1002/prp2.84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317222/
https://www.ncbi.nlm.nih.gov/pubmed/25692009
http://dx.doi.org/10.1002/prp2.84

Ejemplares similares